nodes	percent_of_prediction	percent_of_DWPC	metapath
Alprostadil—Azelaic Acid—TYR—melanoma	0.0187	0.902	CrCbGaD
Alprostadil—Pain localised—Docetaxel—melanoma	0.016	0.0498	CcSEcCtD
Alprostadil—PTGIR—endothelium—melanoma	0.0135	0.11	CbGeAlD
Alprostadil—PTGIR—blood vessel—melanoma	0.0125	0.102	CbGeAlD
Alprostadil—ABCC5—hair follicle—melanoma	0.0106	0.0868	CbGeAlD
Alprostadil—Fibrosis—Carmustine—melanoma	0.01	0.0313	CcSEcCtD
Alprostadil—Hyperaemia—Carmustine—melanoma	0.00947	0.0296	CcSEcCtD
Alprostadil—PTGER2—mammalian vulva—melanoma	0.00899	0.0734	CbGeAlD
Alprostadil—SLCO2A1—neck—melanoma	0.0078	0.0637	CbGeAlD
Alprostadil—Trauma—Bleomycin—melanoma	0.00688	0.0215	CcSEcCtD
Alprostadil—Haemorrhage intracranial—Temozolomide—melanoma	0.00674	0.021	CcSEcCtD
Alprostadil—PTGER1—head—melanoma	0.0061	0.0498	CbGeAlD
Alprostadil—Local reaction—Bleomycin—melanoma	0.00592	0.0185	CcSEcCtD
Alprostadil—SLCO3A1—retina—melanoma	0.00581	0.0474	CbGeAlD
Alprostadil—SLCO2A1—eye—melanoma	0.0058	0.0474	CbGeAlD
Alprostadil—ABCC5—retina—melanoma	0.00526	0.0429	CbGeAlD
Alprostadil—Cerebral haemorrhage—Carmustine—melanoma	0.00517	0.0161	CcSEcCtD
Alprostadil—Disseminated intravascular coagulation—Docetaxel—melanoma	0.00515	0.0161	CcSEcCtD
Alprostadil—SLCO2A1—skin of body—melanoma	0.00505	0.0412	CbGeAlD
Alprostadil—Cerebral haemorrhage—Temozolomide—melanoma	0.00499	0.0156	CcSEcCtD
Alprostadil—SLCO3A1—mammalian vulva—melanoma	0.00465	0.0379	CbGeAlD
Alprostadil—SLCO2A1—mammalian vulva—melanoma	0.0046	0.0376	CbGeAlD
Alprostadil—PTGER2—lymph node—melanoma	0.00451	0.0368	CbGeAlD
Alprostadil—Burning sensation—Carmustine—melanoma	0.00412	0.0129	CcSEcCtD
Alprostadil—Pain in extremity—Vemurafenib—melanoma	0.00393	0.0123	CcSEcCtD
Alprostadil—Influenza-like symptoms—Temozolomide—melanoma	0.00387	0.0121	CcSEcCtD
Alprostadil—PTGIR—head—melanoma	0.00377	0.0308	CbGeAlD
Alprostadil—Injection site pain—Carmustine—melanoma	0.0035	0.0109	CcSEcCtD
Alprostadil—SLCO3A1—head—melanoma	0.00333	0.0271	CbGeAlD
Alprostadil—SLCO2A1—head—melanoma	0.00329	0.0269	CbGeAlD
Alprostadil—Accidental injury—Carmustine—melanoma	0.00323	0.0101	CcSEcCtD
Alprostadil—Wheezing—Bleomycin—melanoma	0.00318	0.00994	CcSEcCtD
Alprostadil—Hyperbilirubinaemia—Temozolomide—melanoma	0.00304	0.00949	CcSEcCtD
Alprostadil—Injection site reaction—Carmustine—melanoma	0.00284	0.00888	CcSEcCtD
Alprostadil—Supraventricular tachycardia—Docetaxel—melanoma	0.00281	0.00876	CcSEcCtD
Alprostadil—Redness—Docetaxel—melanoma	0.00272	0.0085	CcSEcCtD
Alprostadil—Influenza like illness—Temozolomide—melanoma	0.00269	0.00838	CcSEcCtD
Alprostadil—Sepsis—Dactinomycin—melanoma	0.00265	0.00828	CcSEcCtD
Alprostadil—Burning sensation—Docetaxel—melanoma	0.00265	0.00826	CcSEcCtD
Alprostadil—PTGIR—lymph node—melanoma	0.00264	0.0215	CbGeAlD
Alprostadil—Injury—Bleomycin—melanoma	0.00259	0.00808	CcSEcCtD
Alprostadil—Abnormal vision—Carmustine—melanoma	0.0025	0.00779	CcSEcCtD
Alprostadil—Sepsis—Carmustine—melanoma	0.00248	0.00775	CcSEcCtD
Alprostadil—Abnormal vision—Temozolomide—melanoma	0.00241	0.00753	CcSEcCtD
Alprostadil—Diabetes mellitus—Carmustine—melanoma	0.00239	0.00745	CcSEcCtD
Alprostadil—Erythema—Vemurafenib—melanoma	0.00237	0.00738	CcSEcCtD
Alprostadil—SLCO2B1—head—melanoma	0.00236	0.0192	CbGeAlD
Alprostadil—Swelling—Carmustine—melanoma	0.00235	0.00735	CcSEcCtD
Alprostadil—SLCO3A1—lymph node—melanoma	0.00233	0.019	CbGeAlD
Alprostadil—SLCO2A1—lymph node—melanoma	0.00231	0.0188	CbGeAlD
Alprostadil—Back pain—Vemurafenib—melanoma	0.00229	0.00714	CcSEcCtD
Alprostadil—Lethargy—Dactinomycin—melanoma	0.00226	0.00707	CcSEcCtD
Alprostadil—Injury—Carmustine—melanoma	0.00226	0.00705	CcSEcCtD
Alprostadil—Nasal congestion—Temozolomide—melanoma	0.0022	0.00688	CcSEcCtD
Alprostadil—ABCC5—lymph node—melanoma	0.00211	0.0172	CbGeAlD
Alprostadil—ABCC4—head—melanoma	0.00209	0.017	CbGeAlD
Alprostadil—Cough—Vemurafenib—melanoma	0.00206	0.00644	CcSEcCtD
Alprostadil—Hyperbilirubinaemia—Docetaxel—melanoma	0.00202	0.00631	CcSEcCtD
Alprostadil—Dihomo-gamma-linolenic acid—PTGS2—melanoma	0.00202	0.0977	CrCbGaD
Alprostadil—Infection—Vemurafenib—melanoma	0.00192	0.00599	CcSEcCtD
Alprostadil—Hypokalaemia—Carmustine—melanoma	0.00189	0.0059	CcSEcCtD
Alprostadil—Skin disorder—Vemurafenib—melanoma	0.00187	0.00585	CcSEcCtD
Alprostadil—Injection site reaction—Docetaxel—melanoma	0.00183	0.00571	CcSEcCtD
Alprostadil—Hypokalaemia—Temozolomide—melanoma	0.00183	0.0057	CcSEcCtD
Alprostadil—Acute coronary syndrome—Bleomycin—melanoma	0.00181	0.00564	CcSEcCtD
Alprostadil—Hypotension—Vemurafenib—melanoma	0.0018	0.00563	CcSEcCtD
Alprostadil—Myocardial infarction—Bleomycin—melanoma	0.0018	0.00561	CcSEcCtD
Alprostadil—Influenza like illness—Docetaxel—melanoma	0.00179	0.00557	CcSEcCtD
Alprostadil—Haematuria—Bleomycin—melanoma	0.00175	0.00546	CcSEcCtD
Alprostadil—Sweating increased—Temozolomide—melanoma	0.00169	0.00527	CcSEcCtD
Alprostadil—Bronchitis—Temozolomide—melanoma	0.00167	0.00521	CcSEcCtD
Alprostadil—Haemoglobin—Bleomycin—melanoma	0.00165	0.00516	CcSEcCtD
Alprostadil—SLCO2B1—lymph node—melanoma	0.00165	0.0135	CbGeAlD
Alprostadil—Haemorrhage—Bleomycin—melanoma	0.00165	0.00514	CcSEcCtD
Alprostadil—Hypoaesthesia—Bleomycin—melanoma	0.00164	0.00511	CcSEcCtD
Alprostadil—Hyperglycaemia—Carmustine—melanoma	0.00162	0.00505	CcSEcCtD
Alprostadil—Upper respiratory tract infection—Temozolomide—melanoma	0.00161	0.00503	CcSEcCtD
Alprostadil—Pollakiuria—Temozolomide—melanoma	0.0016	0.005	CcSEcCtD
Alprostadil—Sepsis—Docetaxel—melanoma	0.0016	0.00498	CcSEcCtD
Alprostadil—Renal failure—Carmustine—melanoma	0.00157	0.00491	CcSEcCtD
Alprostadil—Hyperglycaemia—Temozolomide—melanoma	0.00156	0.00488	CcSEcCtD
Alprostadil—Urinary tract infection—Carmustine—melanoma	0.00156	0.00486	CcSEcCtD
Alprostadil—Flushing—Bleomycin—melanoma	0.00153	0.00477	CcSEcCtD
Alprostadil—Body temperature increased—Vemurafenib—melanoma	0.00153	0.00476	CcSEcCtD
Alprostadil—Pharyngitis—Dactinomycin—melanoma	0.00152	0.00476	CcSEcCtD
Alprostadil—Swelling—Docetaxel—melanoma	0.00151	0.00472	CcSEcCtD
Alprostadil—Urinary tract infection—Temozolomide—melanoma	0.0015	0.00469	CcSEcCtD
Alprostadil—Cardiac failure congestive—Docetaxel—melanoma	0.00147	0.00459	CcSEcCtD
Alprostadil—ABCC4—lymph node—melanoma	0.00146	0.0119	CbGeAlD
Alprostadil—Sinusitis—Temozolomide—melanoma	0.00145	0.00453	CcSEcCtD
Alprostadil—Haemoglobin—Carmustine—melanoma	0.00144	0.00451	CcSEcCtD
Alprostadil—Haemorrhage—Carmustine—melanoma	0.00144	0.00449	CcSEcCtD
Alprostadil—Erythema—Bleomycin—melanoma	0.00143	0.00447	CcSEcCtD
Alprostadil—Hypoaesthesia—Carmustine—melanoma	0.00143	0.00446	CcSEcCtD
Alprostadil—Flushing—Dactinomycin—melanoma	0.00142	0.00445	CcSEcCtD
Alprostadil—Haemoglobin—Temozolomide—melanoma	0.0014	0.00436	CcSEcCtD
Alprostadil—Haemorrhage—Temozolomide—melanoma	0.00139	0.00433	CcSEcCtD
Alprostadil—Asthenia—Vemurafenib—melanoma	0.00138	0.00432	CcSEcCtD
Alprostadil—Visual impairment—Carmustine—melanoma	0.00138	0.00432	CcSEcCtD
Alprostadil—Hypoaesthesia—Temozolomide—melanoma	0.00138	0.00431	CcSEcCtD
Alprostadil—Pharyngitis—Temozolomide—melanoma	0.00138	0.0043	CcSEcCtD
Alprostadil—Pruritus—Vemurafenib—melanoma	0.00137	0.00426	CcSEcCtD
Alprostadil—Lethargy—Docetaxel—melanoma	0.00136	0.00425	CcSEcCtD
Alprostadil—Urethral disorder—Temozolomide—melanoma	0.00136	0.00425	CcSEcCtD
Alprostadil—Visual impairment—Temozolomide—melanoma	0.00134	0.00418	CcSEcCtD
Alprostadil—Erythema—Dactinomycin—melanoma	0.00134	0.00417	CcSEcCtD
Alprostadil—Pain in extremity—Docetaxel—melanoma	0.00133	0.00417	CcSEcCtD
Alprostadil—Flushing—Carmustine—melanoma	0.00133	0.00416	CcSEcCtD
Alprostadil—Anaemia—Bleomycin—melanoma	0.00132	0.00413	CcSEcCtD
Alprostadil—Diarrhoea—Vemurafenib—melanoma	0.00132	0.00412	CcSEcCtD
Alprostadil—Flushing—Temozolomide—melanoma	0.00129	0.00402	CcSEcCtD
Alprostadil—Dizziness—Vemurafenib—melanoma	0.00128	0.00398	CcSEcCtD
Alprostadil—Erythema—Carmustine—melanoma	0.00125	0.0039	CcSEcCtD
Alprostadil—Cough—Bleomycin—melanoma	0.00125	0.0039	CcSEcCtD
Alprostadil—Anaemia—Dactinomycin—melanoma	0.00124	0.00386	CcSEcCtD
Alprostadil—Rash—Vemurafenib—melanoma	0.00122	0.0038	CcSEcCtD
Alprostadil—Dermatitis—Vemurafenib—melanoma	0.00122	0.0038	CcSEcCtD
Alprostadil—Back pain—Carmustine—melanoma	0.00121	0.00378	CcSEcCtD
Alprostadil—Headache—Vemurafenib—melanoma	0.00121	0.00377	CcSEcCtD
Alprostadil—Erythema—Temozolomide—melanoma	0.00121	0.00377	CcSEcCtD
Alprostadil—Discomfort—Bleomycin—melanoma	0.00121	0.00376	CcSEcCtD
Alprostadil—Oedema—Bleomycin—melanoma	0.00117	0.00365	CcSEcCtD
Alprostadil—Back pain—Temozolomide—melanoma	0.00117	0.00365	CcSEcCtD
Alprostadil—Infection—Bleomycin—melanoma	0.00116	0.00363	CcSEcCtD
Alprostadil—Anaemia—Carmustine—melanoma	0.00116	0.00361	CcSEcCtD
Alprostadil—Nausea—Vemurafenib—melanoma	0.00115	0.00358	CcSEcCtD
Alprostadil—Thrombocytopenia—Bleomycin—melanoma	0.00115	0.00357	CcSEcCtD
Alprostadil—Discomfort—Dactinomycin—melanoma	0.00112	0.00351	CcSEcCtD
Alprostadil—Anaemia—Temozolomide—melanoma	0.00112	0.00349	CcSEcCtD
Alprostadil—Hypotension—Bleomycin—melanoma	0.00109	0.00341	CcSEcCtD
Alprostadil—Oedema—Dactinomycin—melanoma	0.00109	0.0034	CcSEcCtD
Alprostadil—Convulsion—Carmustine—melanoma	0.00108	0.00338	CcSEcCtD
Alprostadil—Infection—Dactinomycin—melanoma	0.00108	0.00338	CcSEcCtD
Alprostadil—Hypertension—Carmustine—melanoma	0.00108	0.00337	CcSEcCtD
Alprostadil—Thrombocytopenia—Dactinomycin—melanoma	0.00107	0.00333	CcSEcCtD
Alprostadil—Cough—Temozolomide—melanoma	0.00105	0.00329	CcSEcCtD
Alprostadil—Convulsion—Temozolomide—melanoma	0.00105	0.00327	CcSEcCtD
Alprostadil—Hypertension—Temozolomide—melanoma	0.00104	0.00326	CcSEcCtD
Alprostadil—Oedema—Carmustine—melanoma	0.00102	0.00319	CcSEcCtD
Alprostadil—Discomfort—Temozolomide—melanoma	0.00102	0.00317	CcSEcCtD
Alprostadil—Infection—Carmustine—melanoma	0.00101	0.00317	CcSEcCtD
Alprostadil—Acute coronary syndrome—Docetaxel—melanoma	0.00101	0.00317	CcSEcCtD
Alprostadil—Renal failure—Docetaxel—melanoma	0.00101	0.00316	CcSEcCtD
Alprostadil—Myocardial infarction—Docetaxel—melanoma	0.00101	0.00315	CcSEcCtD
Alprostadil—Dry mouth—Temozolomide—melanoma	0.00101	0.00314	CcSEcCtD
Alprostadil—Pain—Bleomycin—melanoma	0.001	0.00312	CcSEcCtD
Alprostadil—Thrombocytopenia—Carmustine—melanoma	0.000999	0.00312	CcSEcCtD
Alprostadil—Tachycardia—Carmustine—melanoma	0.000996	0.00311	CcSEcCtD
Alprostadil—Oedema—Temozolomide—melanoma	0.000986	0.00308	CcSEcCtD
Alprostadil—Infection—Temozolomide—melanoma	0.00098	0.00306	CcSEcCtD
Alprostadil—Thrombocytopenia—Temozolomide—melanoma	0.000966	0.00301	CcSEcCtD
Alprostadil—Feeling abnormal—Bleomycin—melanoma	0.000964	0.00301	CcSEcCtD
Alprostadil—Skin disorder—Temozolomide—melanoma	0.000958	0.00299	CcSEcCtD
Alprostadil—Hypotension—Carmustine—melanoma	0.000954	0.00298	CcSEcCtD
Alprostadil—Hyperhidrosis—Temozolomide—melanoma	0.000954	0.00298	CcSEcCtD
Alprostadil—Pain—Dactinomycin—melanoma	0.000933	0.00291	CcSEcCtD
Alprostadil—Haemoglobin—Docetaxel—melanoma	0.000928	0.0029	CcSEcCtD
Alprostadil—Rhinitis—Docetaxel—melanoma	0.000926	0.00289	CcSEcCtD
Alprostadil—Body temperature increased—Bleomycin—melanoma	0.000924	0.00289	CcSEcCtD
Alprostadil—Haemorrhage—Docetaxel—melanoma	0.000923	0.00288	CcSEcCtD
Alprostadil—Hypoaesthesia—Docetaxel—melanoma	0.000919	0.00287	CcSEcCtD
Alprostadil—Pharyngitis—Docetaxel—melanoma	0.000916	0.00286	CcSEcCtD
Alprostadil—Urethral disorder—Docetaxel—melanoma	0.000905	0.00283	CcSEcCtD
Alprostadil—Feeling abnormal—Dactinomycin—melanoma	0.000899	0.00281	CcSEcCtD
Alprostadil—Visual impairment—Docetaxel—melanoma	0.00089	0.00278	CcSEcCtD
Alprostadil—Pain—Carmustine—melanoma	0.000873	0.00272	CcSEcCtD
Alprostadil—Dyspepsia—Temozolomide—melanoma	0.000868	0.00271	CcSEcCtD
Alprostadil—Body temperature increased—Dactinomycin—melanoma	0.000862	0.00269	CcSEcCtD
Alprostadil—Abdominal pain—Dactinomycin—melanoma	0.000862	0.00269	CcSEcCtD
Alprostadil—Flushing—Docetaxel—melanoma	0.000857	0.00268	CcSEcCtD
Alprostadil—Pain—Temozolomide—melanoma	0.000844	0.00263	CcSEcCtD
Alprostadil—Feeling abnormal—Carmustine—melanoma	0.000841	0.00263	CcSEcCtD
Alprostadil—Asthenia—Bleomycin—melanoma	0.000839	0.00262	CcSEcCtD
Alprostadil—Pruritus—Bleomycin—melanoma	0.000827	0.00258	CcSEcCtD
Alprostadil—Feeling abnormal—Temozolomide—melanoma	0.000813	0.00254	CcSEcCtD
Alprostadil—Body temperature increased—Carmustine—melanoma	0.000807	0.00252	CcSEcCtD
Alprostadil—Abdominal pain—Carmustine—melanoma	0.000807	0.00252	CcSEcCtD
Alprostadil—Erythema—Docetaxel—melanoma	0.000804	0.00251	CcSEcCtD
Alprostadil—Asthenia—Dactinomycin—melanoma	0.000783	0.00244	CcSEcCtD
Alprostadil—Abdominal pain—Temozolomide—melanoma	0.00078	0.00243	CcSEcCtD
Alprostadil—Body temperature increased—Temozolomide—melanoma	0.00078	0.00243	CcSEcCtD
Alprostadil—Back pain—Docetaxel—melanoma	0.000778	0.00243	CcSEcCtD
Alprostadil—Muscle spasms—Docetaxel—melanoma	0.000773	0.00241	CcSEcCtD
Alprostadil—Diarrhoea—Dactinomycin—melanoma	0.000746	0.00233	CcSEcCtD
Alprostadil—Anaemia—Docetaxel—melanoma	0.000743	0.00232	CcSEcCtD
Alprostadil—Rash—Bleomycin—melanoma	0.000737	0.0023	CcSEcCtD
Alprostadil—Dermatitis—Bleomycin—melanoma	0.000737	0.0023	CcSEcCtD
Alprostadil—Asthenia—Carmustine—melanoma	0.000732	0.00229	CcSEcCtD
Alprostadil—Syncope—Docetaxel—melanoma	0.000721	0.00225	CcSEcCtD
Alprostadil—Asthenia—Temozolomide—melanoma	0.000708	0.00221	CcSEcCtD
Alprostadil—Loss of consciousness—Docetaxel—melanoma	0.000706	0.00221	CcSEcCtD
Alprostadil—Cough—Docetaxel—melanoma	0.000701	0.00219	CcSEcCtD
Alprostadil—Diarrhoea—Carmustine—melanoma	0.000698	0.00218	CcSEcCtD
Alprostadil—Pruritus—Temozolomide—melanoma	0.000698	0.00218	CcSEcCtD
Alprostadil—Convulsion—Docetaxel—melanoma	0.000696	0.00217	CcSEcCtD
Alprostadil—Nausea—Bleomycin—melanoma	0.000695	0.00217	CcSEcCtD
Alprostadil—Hypertension—Docetaxel—melanoma	0.000694	0.00217	CcSEcCtD
Alprostadil—Rash—Dactinomycin—melanoma	0.000688	0.00215	CcSEcCtD
Alprostadil—Dizziness—Carmustine—melanoma	0.000675	0.00211	CcSEcCtD
Alprostadil—Diarrhoea—Temozolomide—melanoma	0.000675	0.00211	CcSEcCtD
Alprostadil—Dry mouth—Docetaxel—melanoma	0.000669	0.00209	CcSEcCtD
Alprostadil—Oedema—Docetaxel—melanoma	0.000656	0.00205	CcSEcCtD
Alprostadil—Dizziness—Temozolomide—melanoma	0.000652	0.00204	CcSEcCtD
Alprostadil—Infection—Docetaxel—melanoma	0.000652	0.00203	CcSEcCtD
Alprostadil—Nausea—Dactinomycin—melanoma	0.000648	0.00202	CcSEcCtD
Alprostadil—Shock—Docetaxel—melanoma	0.000645	0.00201	CcSEcCtD
Alprostadil—Rash—Carmustine—melanoma	0.000644	0.00201	CcSEcCtD
Alprostadil—Dermatitis—Carmustine—melanoma	0.000643	0.00201	CcSEcCtD
Alprostadil—Thrombocytopenia—Docetaxel—melanoma	0.000642	0.00201	CcSEcCtD
Alprostadil—Tachycardia—Docetaxel—melanoma	0.00064	0.002	CcSEcCtD
Alprostadil—Headache—Carmustine—melanoma	0.000639	0.002	CcSEcCtD
Alprostadil—Skin disorder—Docetaxel—melanoma	0.000637	0.00199	CcSEcCtD
Alprostadil—Rash—Temozolomide—melanoma	0.000622	0.00194	CcSEcCtD
Alprostadil—Dermatitis—Temozolomide—melanoma	0.000621	0.00194	CcSEcCtD
Alprostadil—Headache—Temozolomide—melanoma	0.000618	0.00193	CcSEcCtD
Alprostadil—Hypotension—Docetaxel—melanoma	0.000613	0.00191	CcSEcCtD
Alprostadil—Nausea—Carmustine—melanoma	0.000606	0.00189	CcSEcCtD
Alprostadil—Nausea—Temozolomide—melanoma	0.000586	0.00183	CcSEcCtD
Alprostadil—Dyspepsia—Docetaxel—melanoma	0.000577	0.0018	CcSEcCtD
Alprostadil—Pain—Docetaxel—melanoma	0.000561	0.00175	CcSEcCtD
Alprostadil—Feeling abnormal—Docetaxel—melanoma	0.000541	0.00169	CcSEcCtD
Alprostadil—Abdominal pain—Docetaxel—melanoma	0.000519	0.00162	CcSEcCtD
Alprostadil—Body temperature increased—Docetaxel—melanoma	0.000519	0.00162	CcSEcCtD
Alprostadil—Asthenia—Docetaxel—melanoma	0.000471	0.00147	CcSEcCtD
Alprostadil—Pruritus—Docetaxel—melanoma	0.000464	0.00145	CcSEcCtD
Alprostadil—Diarrhoea—Docetaxel—melanoma	0.000449	0.0014	CcSEcCtD
Alprostadil—Dizziness—Docetaxel—melanoma	0.000434	0.00135	CcSEcCtD
Alprostadil—Rash—Docetaxel—melanoma	0.000414	0.00129	CcSEcCtD
Alprostadil—Dermatitis—Docetaxel—melanoma	0.000413	0.00129	CcSEcCtD
Alprostadil—Headache—Docetaxel—melanoma	0.000411	0.00128	CcSEcCtD
Alprostadil—Nausea—Docetaxel—melanoma	0.00039	0.00122	CcSEcCtD
Alprostadil—PTGER2—Signaling Pathways—KIT—melanoma	0.000104	0.000194	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—PIK3CG—melanoma	0.000104	0.000194	CbGpPWpGaD
Alprostadil—PTGER2—Signaling by GPCR—NRAS—melanoma	0.000104	0.000194	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—EGF—melanoma	0.000103	0.000191	CbGpPWpGaD
Alprostadil—ABCC5—Disease—HLA-A—melanoma	0.000102	0.000191	CbGpPWpGaD
Alprostadil—ABCC5—Disease—TERT—melanoma	0.000102	0.000191	CbGpPWpGaD
Alprostadil—ABCC5—Disease—RAC1—melanoma	0.000102	0.00019	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—ERBB4—melanoma	0.0001	0.000187	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—ERBB4—melanoma	0.0001	0.000187	CbGpPWpGaD
Alprostadil—PTGIR—GPCR downstream signaling—PIK3CB—melanoma	0.0001	0.000187	CbGpPWpGaD
Alprostadil—PTGER1—GPCR downstream signaling—PIK3CB—melanoma	0.0001	0.000187	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—ABCB1—melanoma	0.0001	0.000187	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—CDKN2B—melanoma	9.96e-05	0.000186	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—CDKN2B—melanoma	9.96e-05	0.000186	CbGpPWpGaD
Alprostadil—PTGER2—Signaling by GPCR—MAPK3—melanoma	9.95e-05	0.000185	CbGpPWpGaD
Alprostadil—ABCC5—Disease—HIF1A—melanoma	9.78e-05	0.000182	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—BRAF—melanoma	9.76e-05	0.000182	CbGpPWpGaD
Alprostadil—PTGIR—Hemostasis—PIK3CA—melanoma	9.66e-05	0.00018	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—CD86—melanoma	9.63e-05	0.00018	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—CD86—melanoma	9.63e-05	0.00018	CbGpPWpGaD
Alprostadil—PTGER1—GPCR downstream signaling—CXCL8—melanoma	9.63e-05	0.000179	CbGpPWpGaD
Alprostadil—PTGIR—GPCR downstream signaling—CXCL8—melanoma	9.63e-05	0.000179	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—EDN1—melanoma	9.56e-05	0.000178	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—EDN1—melanoma	9.56e-05	0.000178	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—IGF1—melanoma	9.51e-05	0.000177	CbGpPWpGaD
Alprostadil—PTGER2—Signaling by GPCR—MAPK1—melanoma	9.46e-05	0.000176	CbGpPWpGaD
Alprostadil—PTGER2—Signaling by GPCR—EGFR—melanoma	9.46e-05	0.000176	CbGpPWpGaD
Alprostadil—ABCC4—Hemostasis—PIK3CB—melanoma	9.45e-05	0.000176	CbGpPWpGaD
Alprostadil—PTGIR—Hemostasis—TP53—melanoma	9.35e-05	0.000174	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—CSF2—melanoma	9.34e-05	0.000174	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—CSF2—melanoma	9.34e-05	0.000174	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—FGF1—melanoma	9.34e-05	0.000174	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—FGF1—melanoma	9.34e-05	0.000174	CbGpPWpGaD
Alprostadil—ABCC4—Transmembrane transport of small molecules—ALB—melanoma	9.26e-05	0.000173	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—PRKCA—melanoma	9.21e-05	0.000172	CbGpPWpGaD
Alprostadil—PTGIR—GPCR downstream signaling—IL2—melanoma	9.2e-05	0.000172	CbGpPWpGaD
Alprostadil—PTGER1—GPCR downstream signaling—IL2—melanoma	9.2e-05	0.000172	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—MAP2K1—melanoma	9.19e-05	0.000171	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—E2F1—melanoma	9.14e-05	0.00017	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—E2F1—melanoma	9.14e-05	0.00017	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—ERCC2—melanoma	9.13e-05	0.00017	CbGpPWpGaD
Alprostadil—ABCC4—Platelet activation, signaling and aggregation—AKT1—melanoma	9.13e-05	0.00017	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—PIK3CD—melanoma	9.13e-05	0.00017	CbGpPWpGaD
Alprostadil—PTGIR—Signaling by GPCR—PIK3CB—melanoma	9.1e-05	0.00017	CbGpPWpGaD
Alprostadil—PTGER1—Signaling by GPCR—PIK3CB—melanoma	9.1e-05	0.00017	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—PDGFRA—melanoma	9.05e-05	0.000169	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—PDGFRA—melanoma	9.05e-05	0.000169	CbGpPWpGaD
Alprostadil—PTGER2—GPCR downstream signaling—PIK3CA—melanoma	9.04e-05	0.000169	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—PRKCA—melanoma	8.96e-05	0.000167	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—ITGB3—melanoma	8.96e-05	0.000167	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—ITGB3—melanoma	8.96e-05	0.000167	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—PRKCA—melanoma	8.96e-05	0.000167	CbGpPWpGaD
Alprostadil—PTGIR—Hemostasis—HRAS—melanoma	8.94e-05	0.000167	CbGpPWpGaD
Alprostadil—PTGER2—Signaling by GPCR—KRAS—melanoma	8.94e-05	0.000167	CbGpPWpGaD
Alprostadil—ABCC5—Disease—NOS2—melanoma	8.89e-05	0.000166	CbGpPWpGaD
Alprostadil—ABCC5—Disease—NOTCH1—melanoma	8.81e-05	0.000164	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—SPP1—melanoma	8.78e-05	0.000164	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—SPP1—melanoma	8.78e-05	0.000164	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—MAP2K2—melanoma	8.75e-05	0.000163	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—MAP2K2—melanoma	8.75e-05	0.000163	CbGpPWpGaD
Alprostadil—PTGIR—Signaling by GPCR—CXCL8—melanoma	8.74e-05	0.000163	CbGpPWpGaD
Alprostadil—PTGER1—Signaling by GPCR—CXCL8—melanoma	8.74e-05	0.000163	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—FGF2—melanoma	8.74e-05	0.000163	CbGpPWpGaD
Alprostadil—ABCC4—Hemostasis—IL2—melanoma	8.68e-05	0.000162	CbGpPWpGaD
Alprostadil—ABCC5—Disease—CD80—melanoma	8.63e-05	0.000161	CbGpPWpGaD
Alprostadil—ABCC5—Disease—KIT—melanoma	8.61e-05	0.000161	CbGpPWpGaD
Alprostadil—ABCC5—Disease—APC—melanoma	8.61e-05	0.000161	CbGpPWpGaD
Alprostadil—ABCC5—Disease—EGF—melanoma	8.51e-05	0.000159	CbGpPWpGaD
Alprostadil—PTGIR—Signaling by GPCR—IL2—melanoma	8.36e-05	0.000156	CbGpPWpGaD
Alprostadil—PTGER1—Signaling by GPCR—IL2—melanoma	8.36e-05	0.000156	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—TERT—melanoma	8.33e-05	0.000155	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—TERT—melanoma	8.33e-05	0.000155	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—RAC1—melanoma	8.3e-05	0.000155	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—RAC1—melanoma	8.3e-05	0.000155	CbGpPWpGaD
Alprostadil—PTGER2—Signaling by GPCR—PIK3CA—melanoma	8.21e-05	0.000153	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—MDM2—melanoma	8.18e-05	0.000152	CbGpPWpGaD
Alprostadil—ABCC5—Disease—BRAF—melanoma	8.1e-05	0.000151	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—ERBB2—melanoma	8.06e-05	0.00015	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—HIF1A—melanoma	7.96e-05	0.000148	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—HIF1A—melanoma	7.96e-05	0.000148	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—PIK3CB—melanoma	7.96e-05	0.000148	CbGpPWpGaD
Alprostadil—PTGIR—Hemostasis—AKT1—melanoma	7.9e-05	0.000147	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—CXCL8—melanoma	7.65e-05	0.000143	CbGpPWpGaD
Alprostadil—ABCC5—Disease—MAP2K1—melanoma	7.62e-05	0.000142	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—KDR—melanoma	7.61e-05	0.000142	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—KDR—melanoma	7.61e-05	0.000142	CbGpPWpGaD
Alprostadil—PTGER2—Signaling by GPCR—HRAS—melanoma	7.6e-05	0.000142	CbGpPWpGaD
Alprostadil—ABCC5—Disease—PIK3CD—melanoma	7.57e-05	0.000141	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—CDKN1B—melanoma	7.47e-05	0.000139	CbGpPWpGaD
Alprostadil—PTGER2—GPCR downstream signaling—AKT1—melanoma	7.39e-05	0.000138	CbGpPWpGaD
Alprostadil—ABCC4—Hemostasis—VEGFA—melanoma	7.38e-05	0.000137	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—FN1—melanoma	7.33e-05	0.000137	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—FN1—melanoma	7.33e-05	0.000137	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—CASP3—melanoma	7.32e-05	0.000136	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—IL2—melanoma	7.31e-05	0.000136	CbGpPWpGaD
Alprostadil—ABCC4—Hemostasis—NRAS—melanoma	7.29e-05	0.000136	CbGpPWpGaD
Alprostadil—PTGER2—Signaling by GPCR—IL6—melanoma	7.27e-05	0.000136	CbGpPWpGaD
Alprostadil—ABCC5—Disease—FGF2—melanoma	7.25e-05	0.000135	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—PIK3CG—melanoma	7.21e-05	0.000134	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—NOTCH1—melanoma	7.17e-05	0.000134	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—NOTCH1—melanoma	7.17e-05	0.000134	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—CCND1—melanoma	7.12e-05	0.000133	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—CTNNB1—melanoma	7.05e-05	0.000132	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—CD80—melanoma	7.03e-05	0.000131	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—CD80—melanoma	7.03e-05	0.000131	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—PIK3CG—melanoma	7.01e-05	0.000131	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—APC—melanoma	7.01e-05	0.000131	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—KIT—melanoma	7.01e-05	0.000131	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—APC—melanoma	7.01e-05	0.000131	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—KIT—melanoma	7.01e-05	0.000131	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—PIK3CG—melanoma	7.01e-05	0.000131	CbGpPWpGaD
Alprostadil—PTGIR—Signaling by GPCR—NRAS—melanoma	7.01e-05	0.000131	CbGpPWpGaD
Alprostadil—PTGER1—Signaling by GPCR—NRAS—melanoma	7.01e-05	0.000131	CbGpPWpGaD
Alprostadil—ABCC4—Hemostasis—MAPK3—melanoma	6.98e-05	0.00013	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—PPARG—melanoma	6.96e-05	0.00013	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—EGF—melanoma	6.93e-05	0.000129	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—EGF—melanoma	6.93e-05	0.000129	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—MMP9—melanoma	6.92e-05	0.000129	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—CDKN1A—melanoma	6.89e-05	0.000128	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—PTEN—melanoma	6.88e-05	0.000128	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—NFKB1—melanoma	6.84e-05	0.000128	CbGpPWpGaD
Alprostadil—ABCC5—Disease—MDM2—melanoma	6.78e-05	0.000126	CbGpPWpGaD
Alprostadil—PTGER1—Signaling by GPCR—MAPK3—melanoma	6.72e-05	0.000125	CbGpPWpGaD
Alprostadil—PTGIR—Signaling by GPCR—MAPK3—melanoma	6.72e-05	0.000125	CbGpPWpGaD
Alprostadil—PTGER2—Signaling by GPCR—AKT1—melanoma	6.71e-05	0.000125	CbGpPWpGaD
Alprostadil—ABCC5—Disease—ERBB2—melanoma	6.69e-05	0.000125	CbGpPWpGaD
Alprostadil—ABCC4—Hemostasis—MAPK1—melanoma	6.64e-05	0.000124	CbGpPWpGaD
Alprostadil—ABCC5—Disease—PIK3CB—melanoma	6.6e-05	0.000123	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—BRAF—melanoma	6.59e-05	0.000123	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—BRAF—melanoma	6.59e-05	0.000123	CbGpPWpGaD
Alprostadil—ABCC5—Disease—CD4—melanoma	6.59e-05	0.000123	CbGpPWpGaD
Alprostadil—ABCC5—Disease—PTGS2—melanoma	6.54e-05	0.000122	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—IGF1—melanoma	6.42e-05	0.00012	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—IGF1—melanoma	6.42e-05	0.00012	CbGpPWpGaD
Alprostadil—PTGIR—Signaling by GPCR—MAPK1—melanoma	6.39e-05	0.000119	CbGpPWpGaD
Alprostadil—PTGER1—Signaling by GPCR—MAPK1—melanoma	6.39e-05	0.000119	CbGpPWpGaD
Alprostadil—PTGER1—Signaling by GPCR—EGFR—melanoma	6.39e-05	0.000119	CbGpPWpGaD
Alprostadil—PTGIR—Signaling by GPCR—EGFR—melanoma	6.39e-05	0.000119	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—PIK3CD—melanoma	6.34e-05	0.000118	CbGpPWpGaD
Alprostadil—ABCC4—Hemostasis—KRAS—melanoma	6.27e-05	0.000117	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—ALB—melanoma	6.26e-05	0.000117	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—VEGFA—melanoma	6.21e-05	0.000116	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—MAP2K1—melanoma	6.21e-05	0.000116	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—MAP2K1—melanoma	6.21e-05	0.000116	CbGpPWpGaD
Alprostadil—ABCC5—Disease—CDKN1B—melanoma	6.19e-05	0.000115	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—PIK3CD—melanoma	6.17e-05	0.000115	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—PIK3CD—melanoma	6.17e-05	0.000115	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—STAT3—melanoma	6.15e-05	0.000115	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—NRAS—melanoma	6.13e-05	0.000114	CbGpPWpGaD
Alprostadil—PTGER1—GPCR downstream signaling—PIK3CA—melanoma	6.11e-05	0.000114	CbGpPWpGaD
Alprostadil—PTGIR—GPCR downstream signaling—PIK3CA—melanoma	6.11e-05	0.000114	CbGpPWpGaD
Alprostadil—PTGIR—Signaling by GPCR—KRAS—melanoma	6.04e-05	0.000113	CbGpPWpGaD
Alprostadil—PTGER1—Signaling by GPCR—KRAS—melanoma	6.04e-05	0.000113	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—FGF2—melanoma	5.9e-05	0.00011	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—FGF2—melanoma	5.9e-05	0.00011	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—MAPK3—melanoma	5.88e-05	0.00011	CbGpPWpGaD
Alprostadil—ABCC5—Disease—CTNNB1—melanoma	5.85e-05	0.000109	CbGpPWpGaD
Alprostadil—ABCC4—Hemostasis—PIK3CA—melanoma	5.76e-05	0.000107	CbGpPWpGaD
Alprostadil—ABCC5—Disease—CDKN1A—melanoma	5.72e-05	0.000107	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—MYC—melanoma	5.71e-05	0.000107	CbGpPWpGaD
Alprostadil—ABCC5—Disease—PTEN—melanoma	5.7e-05	0.000106	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—MAPK1—melanoma	5.59e-05	0.000104	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—EGFR—melanoma	5.59e-05	0.000104	CbGpPWpGaD
Alprostadil—ABCC4—Hemostasis—TP53—melanoma	5.57e-05	0.000104	CbGpPWpGaD
Alprostadil—PTGER1—Signaling by GPCR—PIK3CA—melanoma	5.55e-05	0.000103	CbGpPWpGaD
Alprostadil—PTGIR—Signaling by GPCR—PIK3CA—melanoma	5.55e-05	0.000103	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—PIK3CB—melanoma	5.53e-05	0.000103	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—MDM2—melanoma	5.52e-05	0.000103	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—MDM2—melanoma	5.52e-05	0.000103	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—PTGS2—melanoma	5.48e-05	0.000102	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—ERBB2—melanoma	5.45e-05	0.000102	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—ERBB2—melanoma	5.45e-05	0.000102	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—PIK3CB—melanoma	5.37e-05	0.0001	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—PIK3CB—melanoma	5.37e-05	0.0001	CbGpPWpGaD
Alprostadil—ABCC4—Hemostasis—HRAS—melanoma	5.33e-05	9.94e-05	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—KRAS—melanoma	5.28e-05	9.84e-05	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—CXCL8—melanoma	5.17e-05	9.63e-05	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—CXCL8—melanoma	5.17e-05	9.63e-05	CbGpPWpGaD
Alprostadil—PTGER1—Signaling by GPCR—HRAS—melanoma	5.13e-05	9.57e-05	CbGpPWpGaD
Alprostadil—PTGIR—Signaling by GPCR—HRAS—melanoma	5.13e-05	9.57e-05	CbGpPWpGaD
Alprostadil—ABCC5—Disease—STAT3—melanoma	5.1e-05	9.51e-05	CbGpPWpGaD
Alprostadil—ABCC5—Disease—NRAS—melanoma	5.09e-05	9.49e-05	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—CDKN1B—melanoma	5.04e-05	9.4e-05	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—CDKN1B—melanoma	5.04e-05	9.4e-05	CbGpPWpGaD
Alprostadil—PTGIR—GPCR downstream signaling—AKT1—melanoma	4.99e-05	9.3e-05	CbGpPWpGaD
Alprostadil—PTGER1—GPCR downstream signaling—AKT1—melanoma	4.99e-05	9.3e-05	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—CASP3—melanoma	4.94e-05	9.22e-05	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—CASP3—melanoma	4.94e-05	9.22e-05	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—IL2—melanoma	4.94e-05	9.2e-05	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—IL2—melanoma	4.94e-05	9.2e-05	CbGpPWpGaD
Alprostadil—PTGER1—Signaling by GPCR—IL6—melanoma	4.91e-05	9.16e-05	CbGpPWpGaD
Alprostadil—PTGIR—Signaling by GPCR—IL6—melanoma	4.91e-05	9.16e-05	CbGpPWpGaD
Alprostadil—ABCC5—Disease—MAPK3—melanoma	4.87e-05	9.08e-05	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—PIK3CA—melanoma	4.85e-05	9.04e-05	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—CCND1—melanoma	4.81e-05	8.97e-05	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—CCND1—melanoma	4.81e-05	8.97e-05	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—PTEN—melanoma	4.78e-05	8.9e-05	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—CTNNB1—melanoma	4.77e-05	8.88e-05	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—CTNNB1—melanoma	4.77e-05	8.88e-05	CbGpPWpGaD
Alprostadil—ABCC5—Disease—MYC—melanoma	4.74e-05	8.84e-05	CbGpPWpGaD
Alprostadil—ABCC4—Hemostasis—AKT1—melanoma	4.71e-05	8.77e-05	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—TP53—melanoma	4.69e-05	8.75e-05	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—MMP9—melanoma	4.67e-05	8.71e-05	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—MMP9—melanoma	4.67e-05	8.71e-05	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—CDKN1A—melanoma	4.66e-05	8.68e-05	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—CDKN1A—melanoma	4.66e-05	8.68e-05	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—PTEN—melanoma	4.64e-05	8.66e-05	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—PTEN—melanoma	4.64e-05	8.66e-05	CbGpPWpGaD
Alprostadil—ABCC5—Disease—MAPK1—melanoma	4.64e-05	8.64e-05	CbGpPWpGaD
Alprostadil—ABCC5—Disease—EGFR—melanoma	4.64e-05	8.64e-05	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—NFKB1—melanoma	4.62e-05	8.62e-05	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—NFKB1—melanoma	4.62e-05	8.62e-05	CbGpPWpGaD
Alprostadil—PTGIR—Signaling by GPCR—AKT1—melanoma	4.53e-05	8.45e-05	CbGpPWpGaD
Alprostadil—PTGER1—Signaling by GPCR—AKT1—melanoma	4.53e-05	8.45e-05	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—HRAS—melanoma	4.49e-05	8.37e-05	CbGpPWpGaD
Alprostadil—ABCC5—Disease—KRAS—melanoma	4.38e-05	8.16e-05	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—IL6—melanoma	4.3e-05	8.01e-05	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—VEGFA—melanoma	4.2e-05	7.82e-05	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—VEGFA—melanoma	4.2e-05	7.82e-05	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—STAT3—melanoma	4.15e-05	7.74e-05	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—STAT3—melanoma	4.15e-05	7.74e-05	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—NRAS—melanoma	4.14e-05	7.72e-05	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—NRAS—melanoma	4.14e-05	7.72e-05	CbGpPWpGaD
Alprostadil—ABCC5—Disease—PIK3CA—melanoma	4.02e-05	7.5e-05	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—MAPK3—melanoma	3.97e-05	7.4e-05	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—MAPK3—melanoma	3.97e-05	7.4e-05	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—AKT1—melanoma	3.96e-05	7.39e-05	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—MYC—melanoma	3.86e-05	7.2e-05	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—MYC—melanoma	3.86e-05	7.2e-05	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—MAPK1—melanoma	3.78e-05	7.04e-05	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—MAPK1—melanoma	3.78e-05	7.04e-05	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—EGFR—melanoma	3.78e-05	7.04e-05	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—EGFR—melanoma	3.78e-05	7.04e-05	CbGpPWpGaD
Alprostadil—ABCC5—Disease—HRAS—melanoma	3.72e-05	6.94e-05	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—KRAS—melanoma	3.57e-05	6.65e-05	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—KRAS—melanoma	3.57e-05	6.65e-05	CbGpPWpGaD
Alprostadil—ABCC5—Disease—IL6—melanoma	3.56e-05	6.64e-05	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—PIK3CA—melanoma	3.37e-05	6.28e-05	CbGpPWpGaD
Alprostadil—ABCC5—Disease—AKT1—melanoma	3.29e-05	6.13e-05	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—PIK3CA—melanoma	3.28e-05	6.11e-05	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—PIK3CA—melanoma	3.28e-05	6.11e-05	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—TP53—melanoma	3.17e-05	5.91e-05	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—TP53—melanoma	3.17e-05	5.91e-05	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—HRAS—melanoma	3.03e-05	5.65e-05	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—HRAS—melanoma	3.03e-05	5.65e-05	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—IL6—melanoma	2.9e-05	5.41e-05	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—IL6—melanoma	2.9e-05	5.41e-05	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—AKT1—melanoma	2.75e-05	5.13e-05	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—AKT1—melanoma	2.68e-05	4.99e-05	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—AKT1—melanoma	2.68e-05	4.99e-05	CbGpPWpGaD
